<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02573259</url>
  </required_header>
  <id_info>
    <org_study_id>B8011001</org_study_id>
    <secondary_id>2016-003314-27</secondary_id>
    <nct_id>NCT02573259</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors</brief_title>
  <official_title>A PHASE 1, OPEN-LABEL, DOSE ESCALATION AND EXPANSION STUDY OF PF-06801591 IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC MELANOMA, SQUAMOUS CELL HEAD AND NECK CANCER, OVARIAN CANCER, SARCOMA, NON-SMALL CELL LUNG CANCER, UROTHELIAL CARCINOMA OR OTHER SOLID TUMORS.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Protocol B8011001 is a Phase 1, open-label, multi-center, multiple-dose, dose escalation and
      expansion, safety, pharmacokinetics (PK), and pharmacodynamics (PD) study of PF-06801591 in
      previously treated adult patients with locally advanced or metastatic melanoma, SCCHN,
      ovarian carcinoma, sarcoma, NSCLC, urothelial carcinoma or other solid tumors. This is a 2
      Part study whereby the safety and tolerability of increasing dose levels of intravenous (IV)
      or subcutaneous (SC) PF-06801591 was assessed in Part 1. Part 2 expansion is designed to
      further evaluate the safety and efficacy of SC PF-06801591 in patients with NSCLC or
      urothelial carcinoma as well as confirm the recommended Phase 2 dose.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Protocol B8011001 is a Phase 1, two part, open-label, multi center, multiple-dose, safety,
      efficacy, PK, and PD study of PF-06801591 administered intravenously (IV) or subcutaneous
      (SC) in previously treated adult patients with locally advanced or metastatic melanoma,
      squamous cell carcinoma head and neck (SCCHN), ovarian carcinoma, sarcoma, non-small cell
      lung carcinoma (NSCLC), urothelial carcinoma or other solid tumors.

      The first part of the study, Part 1 dose escalation, was designed to assess the safety and
      tolerability of increasing dose levels of IV or SC administered PF-06801591 to establish the
      maximum tolerated dose (MTD) using a modified Toxicity Probability Interval (mTPI) design.
      Part 2 expansion is designed to further evaluate the safety and efficacy of 300 mg of
      PF-06801591 administered SC once every 4 weeks in patients with NSCLC or urothelial carcinoma
      as well as confirm the recommended Phase 2 dose (RP2D). Part 1 enrollment has completed,
      enrollment will only be allowed for Part 2.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 10, 2016</start_date>
  <completion_date type="Anticipated">November 2, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 2, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of participants with Dose-limiting toxicities (DLT)</measure>
    <time_frame>90 days</time_frame>
    <description>A DLT is any of a predefined set of unacceptable adverse events that are observed and that are at least possibly related to the investigational agent(s) OR a DLT is any of a predefined set of unacceptable adverse events (AE), regardless of cause.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Safety Profile</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>Type, incidence, severity, timing, seriousness and relationship to study treatment of adverse events (AE) and any laboratory abnormalities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Estimate clinical efficacy</measure>
    <time_frame>Baseline and every 8-12 weeks through time of confirmed disease progression, unacceptable toxicity, or through study completion (approximately 2 years).</time_frame>
    <description>Objective tumor response, as assessed using the Response Evaluation Criteria in Solid Tumor (RECIST) version 1.1 criteria, immune-related RECIST (irRECIST).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration versus time curve (AUCt)</measure>
    <time_frame>Baseline through end of treatment, an approximate average of 4 months</time_frame>
    <description>AUCt will be calculated for PF- 06801591</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of anti drug antibodies (ADA)</measure>
    <time_frame>Baseline through end of treatment, an approximate average of 4 months</time_frame>
    <description>Incidence of anti drug antibodies (ADA) and neutralizing antibodies (NAb) against PF-06801591.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Receptor Occupancy (RO)</measure>
    <time_frame>0hr at Baseline and through end of treatment, an approximate average of 4 months</time_frame>
    <description>Percentage RO of PF-06801591 in circulating T cells over time following PF-06801591 administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0hr at Baseline and through end of treatment; an approximate average of 4 months</time_frame>
    <description>Cmax will be calculated for PF-06801591</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate preliminary anti-tumor activity of PF-06801591</measure>
    <time_frame>Baseline and every 8-12 weeks through time of confirmed disease progression, unacceptable toxicity, or through study completion (approximately 2 years).</time_frame>
    <description>Time to event endpoints based on RECIST and irRECIST, including time to response (TTR) and time to progression (TTP) as well as progression free survival (PFS) and immune-related (ir) PFS (irPFS) as appropriate, duration of stable disease (DOSD) and irDOSD as appropriate, and duration of response (DOR) and irDOR as appropriate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate overall survival</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Median time to death, proportion of patients alive at 6 months, 1 year, and 2 years.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">147</enrollment>
  <condition>Part 1</condition>
  <condition>MELANOMA</condition>
  <condition>SCCHN</condition>
  <condition>OVCA</condition>
  <condition>SARCOMA</condition>
  <condition>OTHER SOLID TUMORS</condition>
  <condition>Part 1 and 2</condition>
  <condition>NSCLC</condition>
  <condition>UROTHELIAL CARCINOMA</condition>
  <arm_group>
    <arm_group_label>Arm 1 PF-06801591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>0.5 mg/kg IV every 21 days (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 PF-06801591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.0 mg/kg IV every 21 days (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3 PF-06801591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3.0 mg/kg IV every 21 days (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 4 PF-06801591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>10 mg/kg IV every 21 days (Part 1)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 5 PF-06801591</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300 mg SC every 28 days (Part 1 and 2)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06801591</intervention_name>
    <description>IV every 21 days (Part 1)</description>
    <arm_group_label>Arm 1 PF-06801591</arm_group_label>
    <arm_group_label>Arm 2 PF-06801591</arm_group_label>
    <arm_group_label>Arm 3 PF-06801591</arm_group_label>
    <arm_group_label>Arm 4 PF-06801591</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06801591</intervention_name>
    <description>300 mg SC every 28 days (Part 1 and 2)</description>
    <arm_group_label>Arm 5 PF-06801591</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (Part 2 Only):

          -  Histological or cytological diagnosis of locally advanced or metastatic NSCLC or
             urothelial carcinoma who have progressed on or were intolerant to standard of care
             systemic therapy, or for whom standard of care systemic therapy was refused (refusal
             must be documented) or unavailable.

          -  No prior treatment with anti-PD-1 or anti-PD-L1 therapy.

          -  NSCLC patients whose tumor is not known to have ALK or EGFR mutations must have
             progressed on or after no more than 1 prior line of platinum-containing systemic
             therapy or were intolerant or refused standard of care systemic therapy.

          -  NSCLC patients whose tumor is known to have ALK or EGFR mutation must have received
             prior systemic therapies that only include 1 or more lines of ALK or EGFR targeting
             drugs and chemotherapy limited to 1 line of a platinum-based regimen and they must
             have progressed on or after both types of therapies.

          -  Urothelial carcinoma patients must have received up to 2 lines of prior systemic
             therapy and progressed on or after, experienced disease recurrence within 12 months of
             neoadjuvant or adjuvant treatment, were intolerant to, ineligible or refused
             platinum-containing systemic therapy. If urothelial cancer patients are treatment
             naïve and eligible for platinum-containing systemic therapy but are refusing platinum
             chemotherapy, they must also be documented to have previous PD-L1 high status.

          -  Provide archived tumor tissue sample taken within the past 2 years or provide a fresh
             tumor biopsy sample.

          -  At least one measurable lesion as defined by RECIST version 1.1.

          -  Adequate renal, liver, thyroid and bone marrow function.

          -  Performance status 0 or 1.

          -  Patient is capable of receiving study treatment for at least 8 weeks.

        Exclusion Criteria (Part 2 Only)

          -  Active brain or leptomeningeal metastases.

          -  Active, known or suspected autoimmune disease. Patients with vitiligo, type I diabetes
             mellitus, residual hypothyroidism due to autoimmune condition only requiring hormone
             replacement, psoriasis not requiring systemic treatment, or conditions not expected to
             recur in the absence of an external trigger are permitted to enroll. Diagnosis of
             prior immunodeficiency or organ transplant requiring immunosuppressive therapy or
             prior allogeneic bone marrow or hematopoietic stem cell transplant.

          -  Patients with a condition requiring systemic treatment with either corticosteroids
             (&gt;10mg daily prednisone equivalents) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids, and adrenal
             replacement doses &gt;10 mg daily prednisone equivalents are permitted in the absence of
             active autoimmune disease.

          -  Patients with a history of interstitial lung disease, non-infectious pneumonitis, or
             active pulmonary tuberculosis. Those with active lung infections requiring treatment
             are also excluded.

          -  History of Grade ≥3 immune mediated AE (including AST/ALT elevations that where
             considered drug related and cytokine release syndrome) that was considered related to
             prior immune modulatory therapy (eg, immune checkpoint inhibitors, co-stimulatory
             agents, etc.) and required immunosuppressive therapy.

          -  Active hepatitis B or C, HIV/AIDS.

          -  Other potentially metastatic malignancy within past 5 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Administration Office: Clinical Research Unit</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan Medical Center, Department of Radiological Sciences</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ronald Reagan UCLA Medical Center, Drug Information Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Santa Monica UCLA Hematology &amp; Oncology Clinic</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute Pharmacy</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, Multidisciplinary Clinic</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute, Norton Healthcare Pavilion</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Norton Hospital</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester, Cancer Center Pharmacy</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Cancer Hospital Infusion Pharmacy</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Hospitals, The University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7600</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Dickson</city>
        <state>Tennessee</state>
        <zip>37055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Franklin</city>
        <state>Tennessee</state>
        <zip>37067</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Gallatin</city>
        <state>Tennessee</state>
        <zip>37066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Hermitage</city>
        <state>Tennessee</state>
        <zip>37076</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Lebanon</city>
        <state>Tennessee</state>
        <zip>37090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Shelbyville</city>
        <state>Tennessee</state>
        <zip>37160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology, PLLC</name>
      <address>
        <city>Smyrna</city>
        <state>Tennessee</state>
        <zip>37167</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT Uni Hospital OOD</name>
      <address>
        <city>Panagyurishte</city>
        <state>Pazardzhik</state>
        <zip>4500</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complex Oncology Center - Plovdiv EOOD</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;MHAT for Women Health - Nadezhda&quot; OOD</name>
      <address>
        <city>Sofia</city>
        <zip>1330</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SHATOD &quot;Dr. Marko Antonov Markov - Varna&quot; EOOD</name>
      <address>
        <city>Varna</city>
        <zip>9002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Lung Cancer, National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Goyang-si</city>
        <state>Gyeonggi-do</state>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital, B1, Pharmacy</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, St. Vincent's Hospital</name>
      <address>
        <city>Suwon</city>
        <state>Gyeonggi-do</state>
        <zip>16247</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Medical Center</name>
      <address>
        <city>Incheon</city>
        <zip>21565</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Medical Oncology, Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trial Pharmacy, Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Division of Hematology-Oncology, Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ulsan University Hospital</name>
      <address>
        <city>Ulsan</city>
        <zip>44033</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sultan Ismail</name>
      <address>
        <city>Johor Bahru</city>
        <state>Johor</state>
        <zip>81100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Tengku Ampuan Afzan</name>
      <address>
        <city>Kuantan</city>
        <state>Pahang</state>
        <zip>25100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Centre(Crc), Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Umum Sarawak</name>
      <address>
        <city>Kuching</city>
        <state>Sarawak</state>
        <zip>93586</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpitale Pomorskie Sp. z.o.o., Oddzial Onkologii i Radioterapii</name>
      <address>
        <city>Gdynia</city>
        <zip>81-519</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionalny Szpital Specjalistyczny im. dr. Wl. Bieganskiego w Grudziadzu</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych JCI Life Science Park</name>
      <address>
        <city>Krakow</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowiecki Szpital Specjalistyczny im. Dr. Jozefa Psarskiego w Ostrolece, Osrodek Onkologiczny</name>
      <address>
        <city>Ostroleka</city>
        <zip>07-410</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Europejskie Centrum Zdrowia Otwock Szpital im. Fryderyka Chopina</name>
      <address>
        <city>Otwock</city>
        <zip>05-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Onkologii-Instytut im.Marii Sklodowskiej-Curie</name>
      <address>
        <city>Warszawa</city>
        <zip>02-781</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MROI n.a. P.A. Gertsen, filiation of FSBI NMRC of radiology MoH Russia</name>
      <address>
        <city>Obninsk</city>
        <state>Kaluzhskaya Region</state>
        <zip>249036</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sbhi &quot;Lrcod&quot;</name>
      <address>
        <city>Vsevolozhsky District</city>
        <state>Leningrad Region</state>
        <zip>188663</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI ¨Saint-Petersburg clinical scientific practical center of specialized types of</name>
      <address>
        <city>Pesochny Village</city>
        <state>Saint-petersburg</state>
        <zip>197758</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI &quot;ChRCCO and NM&quot;</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MROI n.a. P.A. Gertsen, filiation of FSBI NMRC of radiology MoH Russia</name>
      <address>
        <city>Moscow</city>
        <zip>125284</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BHI of Omsk Region &quot;Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint Stock Company Current medical technologies</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>190013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-governmental Healthcare Institution ¨Railway Clinical Hospital of JSC ¨Russian Railways¨</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBHI &quot;City Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SPb SBHI &quot;City Clinical Oncology Dispensary&quot;</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joint-Stock Company Current medical technologies</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190121</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI YaR ¨Regional clinical oncology hospital¨</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Institution &quot;City Clinical Hospital #4&quot; of Dnipro City Council, Department of</name>
      <address>
        <city>Dnipro</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution &quot;Carpathian Clinical Oncological Center&quot;, IV surgery department.</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>79018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grigoriev Radiological Institute of the National Academy of Medical Sciences of Ukraine,</name>
      <address>
        <city>Kharkiv</city>
        <zip>61024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Institution of Kharkiv Regional Council &quot;Regional Clinical Specialized Health</name>
      <address>
        <city>Kharkiv</city>
        <zip>61166</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Specialized Clinic &quot;Prognosis Optima&quot; LLC</name>
      <address>
        <city>Kyiv</city>
        <zip>03126</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Communal Institution Sumy Regional Clinical Oncological Dispensary, Oncology,</name>
      <address>
        <city>Sumy</city>
        <zip>40030</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Non-profit Institution &quot;Central City Clinical Hospital&quot; of Uzhhorod City Council,</name>
      <address>
        <city>Uzhhorod</city>
        <zip>88000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Podilskiy regional center of oncology</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Communal Institution ¨Zaporizhzhya Regional Clinical Oncological Dispensary¨</name>
      <address>
        <city>Zaporizhzhya</city>
        <zip>69040</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Singapore</country>
  </removed_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B8011001</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 6, 2015</study_first_submitted>
  <study_first_submitted_qc>October 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2015</study_first_posted>
  <last_update_submitted>July 2, 2020</last_update_submitted>
  <last_update_submitted_qc>July 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>pharmacodynamics</keyword>
  <keyword>open label</keyword>
  <keyword>dose response</keyword>
  <keyword>multiple ascending dose</keyword>
  <keyword>immunogenicity</keyword>
  <keyword>recommended phase 2 dose</keyword>
  <keyword>subcutaneous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Melanoma</mesh_term>
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

